Patients 0 8 0 8 O
previously 9 19 9 19 O
enrolled 20 28 20 28 O
in 29 31 29 31 O
etrolizumab 32 43 32 43 B-treatment
Phase 44 49 44 49 I-treatment
III 50 53 50 53 I-treatment
study 54 59 54 59 I-treatment
GA29144 60 67 60 67 I-treatment
who 68 71 68 71 O
meet 72 76 72 76 O
the 77 80 77 80 O
eligibility 81 92 81 92 O
criteria 93 101 93 101 O
for 102 105 102 105 O
open 106 110 106 110 O
- 110 111 110 111 O
label 111 116 111 116 O
etrolizumab 117 128 117 128 O
as 129 131 129 131 O
described 132 141 132 141 O
in 142 144 142 144 O
the 145 148 145 148 O
protocol 149 157 149 157 O

